ストックスクリーナーアプリを入手
23.27
0.73%
-0.17
前日終値:
$23.44
開ける：
$23.27
24時間の取引高:
701.47K
Relative Volume:
0.65
時価総額：
$2.23B
収益：
-
当期純損益:
$-115.88M
株価収益率:
-15.04
EPS:
-1.5468
ネットキャッシュフロー:
$-104.72M
1週間 パフォーマンス:
-1.44%
1か月 パフォーマンス:
-11.82%
6か月 パフォーマンス:
-10.81%
1年 パフォーマンス:
+27.58%
1日の値動き範囲:
$22.62
$23.48
1週間の範囲:
$21.58
$25.36
52週間の値動き範囲:
$14.90
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
EWTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
23.27 | 2.23B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-01-22 | 開始されました | Stifel | Hold |
| 2024-11-22 | 開始されました | Evercore ISI | Outperform |
| 2024-03-07 | 開始されました | Piper Sandler | Overweight |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2022-08-25 | ダウングレード | Goldman | Neutral → Sell |
| 2022-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-28 | 開始されました | Goldman | Neutral |
すべてを表示
Edgewise Therapeutics Inc (EWTX) 最新ニュース
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 9.3%Should You Buy? - MarketBeat
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Benzinga
EFG Asset Management North America Corp. Invests $1.10 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Intech Investment Management LLC Boosts Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Major Phase 2 Trial Results: Edgewise's New HCM Drug Could Transform Patient Care - StockTitan
EDG-4131 active in model of Becker muscular dystrophy - BioWorld Online
Victory Capital Management Inc. Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Charles Schwab Investment Management Inc. Has $14.35 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.5%Should You Sell? - MarketBeat
Truist maintains Buy rating on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownShould You Sell? - MarketBeat
(EWTX) Technical Data - Stock Traders Daily
Amundi Buys 191,267 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.3%Here's What Happened - MarketBeat
Edgewise Therapeutics chief scientific officer sells $6,004 in stock By Investing.com - Investing.com Australia
Ratios Uncovered: Breaking Down Edgewise Therapeutics Inc (EWTX)’s Trailing Twelve Months Metrics - The Dwinnex
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference - BioSpace
Edgewise Therapeutics CEO Kevin Koch sells $3,000 in stock By Investing.com - Investing.com South Africa
Scotiabank Begins Coverage on Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics CEO Kevin Koch sells $3,000 in stock - Investing.com
Breakthrough Drug Sevasemten Delivers Positive Results for Becker Muscular Dystrophy Patients - StockTitan
Edgewise Therapeutics Sees Unusually Large Options Volume (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 4.9%Still a Buy? - MarketBeat
Edgewise Therapeutics: More Expensive Now, But Much More Derisked (NASDAQ:EWTX) - Seeking Alpha
Piper Sandler maintains $51 target on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Holdings Lessened by Candriam S.C.A. - MarketBeat
Why Is Edgewise Therapeutics Inc (NASDAQ: EWTX) Falling? - Stocks Register
Edgewise Therapeutics (NASDAQ:EWTX) Research Coverage Started at Scotiabank - Defense World
Trend Tracker for (EWTX) - Stock Traders Daily
Q1 EPS Forecast for Edgewise Therapeutics Lowered by Analyst - MarketBeat
Equities Analysts Issue Forecasts for EWTX FY2026 Earnings - MarketBeat
Scotiabank Initiates Coverage of Edgewise Therapeutics (EWTX) with Sector Outperform Recommendation - Nasdaq
Edgewise Therapeutics' (EWTX) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Edgewise Therapeutics Sees Unusually High Options Volume (NASDAQ:EWTX) - Defense World
Scotiabank sets $50 target for Edgewise Therapeutics stock - Investing.com India
Wedbush Lowers Earnings Estimates for Edgewise Therapeutics - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Edgewise Therapeutics Inc (EWTX) 財務データ
収益
当期純利益
現金流量
EPS
Edgewise Therapeutics Inc (EWTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Mar 07 '25 |
Sale |
30.02 |
200 |
6,004 |
14,863 |
| KOCH KEVIN | President and CEO |
Mar 07 '25 |
Option Exercise |
0.18 |
100 |
18 |
14,578 |
| KOCH KEVIN | President and CEO |
Mar 07 '25 |
Sale |
30.00 |
100 |
3,000 |
14,478 |
| Russell Alan J | Chief Scientific Officer |
Feb 05 '25 |
Option Exercise |
0.18 |
8,015 |
1,443 |
22,878 |
| Russell Alan J | Chief Scientific Officer |
Feb 06 '25 |
Option Exercise |
0.18 |
1,200 |
216 |
16,063 |
| Russell Alan J | Chief Scientific Officer |
Feb 05 '25 |
Sale |
30.02 |
8,015 |
240,623 |
14,863 |
| Russell Alan J | Chief Scientific Officer |
Feb 06 '25 |
Sale |
30.13 |
1,200 |
36,153 |
14,863 |
| KOCH KEVIN | President and CEO |
Feb 06 '25 |
Option Exercise |
13.11 |
900 |
11,799 |
15,378 |
| KOCH KEVIN | President and CEO |
Feb 05 '25 |
Option Exercise |
0.18 |
8,636 |
1,554 |
23,114 |
| KOCH KEVIN | President and CEO |
Feb 05 '25 |
Sale |
30.03 |
8,636 |
259,298 |
14,478 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):